Curriculum Vitaes

hayashi masamichi

  (林 正道)

Profile Information

Affiliation
School of Medicine Faculty of Medicine, Fujita Health University
Degree
博士(医学)

Other name(s) (e.g. nickname)
許可しない
J-GLOBAL ID
201501009775390763
researchmap Member ID
7000013249

Misc.

 14
  • Sumito Isogai, Masamichi Hayashi, Naoki Yamamoto, Mariko Morishita, Tomoyuki Minezawa, Takuya Okamura, Tami Hoshino, Mitsushi Okazawa, Kazuyoshi Imaizumi
    Allergology international : official journal of the Japanese Society of Allergology, 62(3) 367-73, Sep, 2013  Peer-reviewed
    BACKGROUND: Although a challenge test using non-steroidal anti-inflammatory drugs (NSAIDs) is crucial for diagnosis of aspirin-induced asthma (AIA), it also has drawbacks in terms of possible side effects. Therefore, alternative in-vitro diagnostic methods for AIA are awaited. METHODS: Nineteen stable non-AIA patients (9 males and 10 females; mean age, 49.4 ± 4.8 years), and 20 AIA patients (9 males and 11 females; mean age, 51.1 ± 4.8 years) were enrolled in this study. CD11b and CD16 expressions on the peripheral-blood granulocytes after administration of aspirin and different concentrations of PGE2 in vitro were examined using flowcytometry. RESULTS: Aspirin induced a significant increase in CD11b expression on eosinophils (CD16 negative granulocytes) in 19 AIA patients and one non-AIA patient. Increase in CD11b expression on eosinophils by aspirin administration was suppressed by PGE2 in a dose-dependent manner. CONCLUSIONS: The measurement of CD11b expression on peripheral-blood eosinophils showed very high sensitivity and specificity of (-95%) in diagnosing AIA. Although this method requires laboratory facilities for flowcytometry, it may be very useful in diagnosis of AIA without side effects. In addition, PGE2 may be involved in regulation of CD11b expression on eosinophils by aspirin administration.
  • Hideyasu Shimizu, Masamichi Hayashi, Yuji Saito, Yuki Mieno, Yasuo Takeuchi, Fumihiko Sasaki, Hiroki Sakakibara, Kensei Naito, Mitsushi Okazawa
    Cough, 9(1) 4, Feb 7, 2013  Peer-reviewed
    Background: Chronic cough is one of the most challenging symptoms to diagnose and treat, not only because of the variety of underlying disorders but also its varying susceptibility to treatments. Etiological studies of chronic cough vary depending on the clinical settings and the particular interests of investigators.Objectives: The purposes of this study were first to categorize the etiology of chronic cough by its response to systematic diagnostic treatments starting from the β2 agonist and second to sub-categorize β2 agonist responsive cough (BRC) by the airway hyperresponsiveness.Methods: One hundred and eighty-four never-smokers received the maximal dose of procaterol to diagnose BRC. BRC was sub-categorized into two groups with or without airway hyperresponsiveness measured by the methacholine challenge test. Sinobronchial syndrome (SBS) was diagnosed by postnasal drip symptoms and by the response to clarythromycin and carbocysteine. Atopic cough (AC) was diagnosed by the evidence of atopy and the response to cetirizine hydrochloride. Gastroesophageal reflux disease (GERD) was diagnosed by the response to rabeprazole sodium. Since we did not investigate eosinophil counts in the tissue or in the induced sputum, no diagnosis of eosinophilic bronchitis was made.Results: One hundred and nine patients had BRC. Twenty-three of them had bronchial asthma (BA), 53 had cough variant asthma (CVA) and 33 had non-hyperresponsive BRC (NHBRC). Thirty-one patients had GERD, 27 had AC and 14 had SBS. Twenty-five patients had more than one diagnosis in combination, while 6 had other miscellaneous diseases. Twelve patients were undiagnosed and 11 dropped out of the study.Conclusions: The majority of chronic cough was BRC. NHBRC was a new chronic cough entity. GERD is a common cause of chronic cough in Japan, as in Western countries. AC and SBS are also causes of chronic cough in Japan.Trial registration: University hospital medical information network (UMIN 000007483). © 2013 Shimizu et al. licensee BioMed Central Ltd.
  • 磯谷澄都, 今泉和良, 岡澤光芝, 林 正道, 峯澤智之
    平成24年度厚生労働科学研究費補助金 難治性疾患等克服研究事業(免疫アレルギー疾患等予防・治療研究事業 免疫アレルギー疾患分野), 69, 2013  
  • 磯谷澄都, 今泉和良, 岡澤光芝, 林 正道, 峯澤智之
    平成24年度 厚生労働科学研究費補助金 難治性疾患等克服研究事業 免疫アレルギー疾患等予防・治療研究事業 研究報告書(免疫アレルギー疾患分野), 288-292, 2013  
  • 山口哲平, 中西 亨, 磯谷澄都, 林 正道, 星野多美, 魚津桜子, 森下真梨子, 峯澤智之, 岡澤光芝, 今泉和良
    肺癌, 53(4) 318-323, 2013  Peer-reviewed

Books and Other Publications

 5

Presentations

 75